Medical breakthrough: A novel mode of action uncouples the physiological function of glutamate-gated NMDA receptors (NMDARs) from their toxic effects in neurodegeneration.
First-in-Class NMDAR/TRPM4 (N/T) Interface Inhibitors selectively abolish extrasynaptic NMDARs-induced glutamate neurotoxicity but preserve the effects of synaptic NMDARs on neuronal survival and memory.
Our approach stops neurodegeneration, restores function, and maintains brain health.
